semaglutide oral Rybelsus
Selected indexed studies
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2023) [PMID:37385278]
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. (N Engl J Med, 2025) [PMID:40934115]
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. (N Engl J Med, 2019) [PMID:31185157]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) pubmed
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. (2019) pubmed
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. (2025) pubmed
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. (2023) pubmed
- Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. (2021) pubmed
- Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. (2025) pubmed
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. (2025) pubmed
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. (2019) pubmed
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. (2017) pubmed
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. (2019) pubmed